Back to discover
§ The cross-read
BMY vs REGN
BMY's Section-2 severe IRA Margin Compression risk is the dominant variable in any cross-read.
Fair-value ladder
Fair-value ladder unavailable — one or both tickers have no published mid fair value.
Aligned scorecards
BMYREGN
| BMYBristol-Myers Squibb Company | REGNRegeneron Pharmaceuticals Inc. | |
|---|---|---|
| Trend | - | - |
| Price | - | - |
| Fair value | - | - |
| FV range | - | - |
| Upside | - | - |
| Rating | Aanhouden | Aanhouden |
| Confidence | - | - |
| Moat | - | - |
| Archetype | - | - |
| Sector | Health Care | Health Care |
| Analyzed | - | - |
9-category scorecards
BMY
Bristol-Myers Squibb Company
Valuation
5.0/10
0.11x
Management
7.3/10
0.11x
Balance Sheet
3.5/10
0.11x
Profitability
7.5/10
0.11x
Revenue Growth
4.5/10
0.11x
Risk Assessment
5.0/10
0.11x
Competitive Moat
6.5/10
0.11x
Earnings Quality
8.0/10
0.11x
Capital Efficiency
7.5/10
0.11x
Weighted Overall
6.1/10
REGN
Regeneron Pharmaceuticals Inc.
Valuation
5.0/10
0.11x
Management
6.9/10
0.11x
Balance Sheet
8.5/10
0.11x
Profitability
6.5/10
0.11x
Revenue Growth
7.5/10
0.11x
Risk Assessment
9.0/10
0.11x
Competitive Moat
9.0/10
0.11x
Earnings Quality
6.0/10
0.11x
Capital Efficiency
6.5/10
0.11x
Weighted Overall
7.2/10